ARCH Venture Partners
Coverage of ARCH Venture Partners in the Nexus archive.
- STAT+: Ophthalmology venture grabs investors’ attention, raises $330 million
Ollin Biosciences, a startup developing treatments for eye diseases, raised $330 million in a Series B funding round led by TCGX and ARCH Venture Partners. The company is preparing for a Phase 3 trial of a treatment targeting diabetic macular edema and wet age-related macular degeneration.
- Jeff Bezos raises $12B for AI that builds things
Jeff Bezos and Vik Bajaj have raised $12 billion for Prometheus, a $41 billion AI startup aiming to revolutionize engineering and manufacturing by creating an 'artificial general engineer.' The company uses data from the physical world to accelerate production of products like skyscrapers and jet engines, with backing from JPMorgan, BlackRock, and other major investors.
- STAT+: CREATE Medicines, a biotech company developing CAR-T therapies, raises $122 million
CREATE Medicines, a biotech company, raises $122 million to develop CAR-T therapies, expanding its pipeline and researching autoimmune diseases. The company was cofounded by Siddhartha Mukherjee and recently rebranded from Myeloid Therapeutics. This funding will propel the company's first CAR-T candidates through human trials.